Latest Insider Transactions at Psychemedics Corp (PMD)
This section provides a real-time view of insider transactions for Psychemedics Corp (PMD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PSYCHEMEDICS CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PSYCHEMEDICS CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 17
2023
|
Michael Weisenhoff |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+50.0%
|
-
|
|
Aug 17
2023
|
Charles M Doucot Executive Vice President |
SELL
Open market or private sale
|
Direct |
12,700
-35.33%
|
$50,800
$4.66 P/Share
|
|
Aug 17
2023
|
Darius G Nevin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+37.84%
|
-
|
|
Aug 17
2023
|
Peter Kamin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+5.58%
|
-
|
|
Aug 17
2023
|
Robyn C Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+26.42%
|
-
|
|
Aug 17
2023
|
Andrew Reynolds Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+33.33%
|
-
|
|
May 22
2023
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,500
-0.6%
|
$6,000
$4.93 P/Share
|
|
May 22
2023
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
825
-2.24%
|
$3,300
$4.93 P/Share
|
|
May 22
2023
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
375
-1.02%
|
$1,500
$4.93 P/Share
|
|
May 15
2023
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,725
-0.69%
|
$6,900
$4.87 P/Share
|
|
May 15
2023
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.91%
|
$1,348
$4.87 P/Share
|
|
May 15
2023
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
900
-2.39%
|
$3,600
$4.87 P/Share
|
|
Dec 16
2022
|
Michael I Schaffer VP of Laboratory Operations |
BUY
Open market or private purchase
|
Direct |
100
+0.27%
|
$400
$4.95 P/Share
|
|
Nov 11
2022
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,350
-3.46%
|
$8,100
$6.18 P/Share
|
|
Nov 11
2022
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,625
-1.04%
|
$15,750
$6.18 P/Share
|
|
Nov 11
2022
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
525
-1.4%
|
$3,150
$6.18 P/Share
|
|
Aug 12
2022
|
Darius G Nevin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Aug 12
2022
|
Peter Kamin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+3.88%
|
-
|
|
May 20
2022
|
Raymond C Kubacki Jr Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+7.34%
|
-
|
|
May 20
2022
|
Michael I Schaffer VP of Laboratory Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+11.73%
|
-
|
|
May 20
2022
|
Andrew Limbek Vice President & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+33.55%
|
-
|
|
May 20
2022
|
Charles M Doucot Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+21.99%
|
-
|
|
May 20
2022
|
Andrew Reynolds Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+46.15%
|
-
|
|
May 20
2022
|
Walter S Tomenson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+13.89%
|
-
|
|
May 20
2022
|
Fred J Weinert Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+14.36%
|
-
|
|
May 20
2022
|
Robyn C Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+32.43%
|
-
|
|
May 13
2022
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,725
-0.74%
|
$10,350
$6.44 P/Share
|
|
May 13
2022
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-1.02%
|
$2,022
$6.44 P/Share
|
|
May 13
2022
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
900
-3.11%
|
$5,400
$6.44 P/Share
|
|
May 13
2022
|
Andrew Limbek Vice President & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
600
-8.04%
|
$3,600
$6.44 P/Share
|
|
Apr 20
2022
|
Peter Kamin Director |
BUY
Open market or private purchase
|
Indirect |
7,558
+2.42%
|
$45,348
$6.72 P/Share
|
|
Apr 20
2022
|
Peter Kamin Director |
BUY
Open market or private purchase
|
Direct |
8,100
+3.65%
|
$48,600
$6.72 P/Share
|
|
Apr 19
2022
|
Peter Kamin Director |
BUY
Open market or private purchase
|
Indirect |
27,485
+5.37%
|
$164,910
$6.52 P/Share
|
|
Apr 08
2022
|
Peter Kamin Director |
BUY
Open market or private purchase
|
Indirect |
4,000
+1.91%
|
$24,000
$6.79 P/Share
|
|
Apr 07
2022
|
Peter Kamin Director |
BUY
Open market or private purchase
|
Indirect |
3,000
+1.47%
|
$18,000
$6.68 P/Share
|
|
Apr 05
2022
|
Fred J Weinert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.65%
|
$4,000
$4.07 P/Share
|
|
Apr 05
2022
|
Andrew Reynolds Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 16
2022
|
Peter Kamin Director |
BUY
Open market or private purchase
|
Indirect |
4,000
+3.34%
|
$24,000
$6.51 P/Share
|
|
Jan 25
2022
|
Andrew Limbek Vice President & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
37
-0.49%
|
$259
$7.39 P/Share
|
|
Nov 12
2021
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,062
-1.29%
|
$24,496
$8.5 P/Share
|
|
Nov 12
2021
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-1.83%
|
$4,896
$8.5 P/Share
|
|
Nov 12
2021
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,575
-5.16%
|
$12,600
$8.5 P/Share
|
|
May 13
2021
|
Charles M Doucot Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+28.24%
|
-
|
|
May 13
2021
|
Andrew Limbek Vice President & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+44.44%
|
-
|
|
May 13
2021
|
Raymond C Kubacki Jr Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+8.83%
|
-
|
|
May 13
2021
|
Harry F Sr Connick Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+10.88%
|
-
|
|
May 13
2021
|
Walter S Tomenson Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+14.99%
|
-
|
|
May 13
2021
|
Fred J Weinert Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+15.81%
|
-
|
|
May 13
2021
|
Robyn C Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+45.83%
|
-
|
|
May 13
2021
|
Michael I Schaffer VP of Laboratory Operations |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+11.84%
|
-
|